PeptiDream Inc.
News Release
Using the PDPS platform in joint research with MSD, a milestone was achieved and a milestone fee was received. Impact on earnings guidance is unchanged at this time and not disclosed.
Key Figures
- Milestone fee: Unknown
- Earnings forecast for fiscal year ending December 2026: Already factored in, unchanged
- Joint research with MSD: PCC program, PDPS technology
AI要約
Summary of the News
PeptiDream Inc. has achieved a significant milestone in the PCC program under joint research and development with MSD and has received a milestone fee. This result demonstrates the utility and versatility of the PDPS platform, and PeptiDream Inc. will continue close collaboration with MSD to advance the program. The amount related to this milestone has not been disclosed.
Impact on Business and Financials
This announcement concerns a contract-based milestone fee and has already been factored into the full-year earnings forecast for the fiscal year ending December 2026; there is no change to the current earnings forecast. If any changes to the earnings forecast occur, they will be disclosed promptly.
PeptiDream Inc.
Company overview · Stock price · Financial data · All IR
